Compounds for control of appetite

a technology of neuropeptide y and y4 receptor, which is applied in the direction of peptide/protein ingredients, drug compositions, metabolic disorders, etc., can solve the problems of refractory obesity subpopulation, vestibular disturbance, hallucination,

Inactive Publication Date: 2007-08-23
CINCINNATI UNIV OF
View PDF19 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The effective treatment of obesity, however, remains a largely unachieved goal.
Although weight loss can be achieved with such agents, their use is restricted due to CNS side-effects, potential addiction liability and the production of tolerance to their actions, with chronic administration leading to potential depression, vestibular disturbances, hallucinations and addiction, as well as interference with the actions of other drugs, such as MAO inhibitors and antihypertensives.
There is also a subpopulation of obese patients that is refractory to present anorectic drug treatments.
NPY has also been reported to produce coronary artery vasoconstriction and thereby may decrease myocardial blood flow resulting in myocardial ischemia.
Such a circumstance can result in angina pectoris or, under more severe circumstances, may result in myocardial infarction and death.
Native PP may not be an ideal candidate for suppressing food intake because of its short half-life of about six minutes and its interactions with Y5 receptors.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds for control of appetite
  • Compounds for control of appetite
  • Compounds for control of appetite

Examples

Experimental program
Comparison scheme
Effect test

example i

[0304] Analogs of PP(32-36) and, more specifically, the pentapeptide parallel dimer,

which includes the tetra-methylene spacer, was synthesized generally by standard stepwise t-Boc-solid phase methods and purified by reversed phase chromatography as is known in the art (J. Med. Chem. 2000, 49, 3420-3427).

[0305] More specifically, to obtain the parallel dimer, B-74, N-α-Boc-D / L-diamino-dicarboxylic acids (0.5 equiv) was coupled manually to the N-terminus of the protected pentapeptide peptide resin in the presence of equivalent quantities of DIC, HOBT, and DIEA. Free-peptide amides then were obtained by standard HF cleavage of the protected peptide-MBHA resin in the presence of about 5% p-cresol and about 2.5% thiocresol and purified by reversed phase chromatography.

example ii

[0306] To study the feeding patterns of animals treated with B-74, seven to eight week old C57BL / 6 male mice (Harlan Laboratories, Indianapolis, Ind.) were individually housed in cages in a temperature controlled room (25° C.) under 12-hour light / dark cycles. Mice had free access to water and standard chow and were acclimatized to daily ip saline injections. After one week of acclimatizing, mice were fasted for 18 hours before the experiment, and saline (0.1 ml), hPP (10 mmol / mice), or B-74 (100 nmol / mice) in saline (0.1 ml) were injected intraperitoneally. Food was provided ten (10) minutes later, and the 2 and 4 hour food intake was monitored. Statistical significance was determined by ANOVA, with individual means being compared post-hoc by Tukey's corrected t-test.

[0307] The results are shown in FIG. 1. Specifically, intraperitoneal (ip) injections of PP (10 nmol / mice) and B-74 (100 nmol / mice) inhibited the 2 h and 4 h food intake to a greater extent than the control.

example iii

[0308] The PYY (22-36) analog, N-α-Ac[Nle24,28, Trp30, Nva31, ψ35 / 36]PYY(22-36)-NH2 (SEQ. ID. NO. 7), referred to as B-48, wherein ψ is —CH2-NH—, was similarly synthesized by standard stepwise t-Boc-solid phase methods and purified by reversed phase chromatography as is known in the art according, and as referred to in Example I.

[0309] To further study the feeding patterns of animals treated with B-48, experiments were performed in seven to eight week old C57BL / 6 male mice (Harlan Laboratories, Indianapolis, Ind.) after acclimatization of mice for one week. More specifically, in preliminary studies, overnight (18 h) fasted animals were injected (ip) with 0.1 ml of saline or saline (0.1 ml) containing various concentrations of B-48 (0.025, 0.050, 0.100 or 0.150 μmol / mice) (n=8-10 per group). The mice were provided with a known quantity of chow 10 min later. The food intake was monitored over 1-24 h. The results (not shown) revealed that a minimum dose of 0.050 μmol / mice of B-48 was ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
concentrationsaaaaaaaaaa
volumeaaaaaaaaaa
Login to view more

Abstract

This invention relates generally to neuropeptide Y (“NPY”) Y4 receptor agonists including pancreatic polypeptide (PP), analogs thereof, and peptide fragments of PP, e.g. PP(32-36), and analogs thereof, to pharmaceutical compositions containing such Y4 receptor agonists, and to methods for treatment of mammals using the same. The NPY Y4 receptor agonists may be administered to mammals either alone or in combination with NPY Y2 receptor agonists including peptide YY (PYY) (3-36), analogs thereof, and to peptide fragments of PYY(3-36), e.g. PYY(22-36) and PYY(25-36), and analogs thereof, such as to control food intake in mammals, blood pressure, cardiovascular response, libido, circadian rhythm, hyperlipidimia, chronic pancreatitis, and nonalcoholic fatty liver disease including nonalcoholic steatohepatitis.

Description

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH [0001] The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of Grant / Contract No. GM47122-08S1 awarded by the National Institutes of Health.FIELD OF THE INVENTION [0002] This invention relates generally to neuropeptide Y (“NPY”) Y4 receptor agonists including pancreatic polypeptide (PP), analogs thereof, and to peptide fragments of PP, and analogs thereof, and to methods for treatment of mammals using the same and, more specifically, the invention is directed to NPY Y4 receptor agonists including PP(32-36), and analogs thereof, to pharmaceutical compositions containing such pentapeptides, and to methods of treatment of mammals using such pentapeptides. The NPY Y4 receptor agonists may be administered to mammals either alone or in combination with NPY Y2 receptor agonists including peptide YY (PYY...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/10C07K7/08
CPCA61K38/00C07K7/06C07K14/57545C07K7/08A61P3/04
Inventor BALASUBRAMANIAM, AMBIKAIPAKAN
Owner CINCINNATI UNIV OF
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap